Superior outcomes and lower outpatient costs with scale-up of antiretroviral therapy at the GHESKIO clinic in Port-Au-Prince, Haiti

Journal of Acquired Immune Deficiency Syndromes

Volumn 66, Issue 4, 2014, Pages

  Riviere, Cynthia ^a   Faust, Elizabeth ^b   Miller, Thane ^c   Beck, Eduard J ^d   Baruwa, Elaine ^e   Severe, Patrice ^a   Severe, Karine ^a   Riché, Claudia Thomas ^a   Cassagnol, Rachelle ^e   Atwood, Sidney ^f   Esperance, Morgan ^f   Webster, Lauren ^a   Cremieux, Pierre ^b   Pape, Jean W ^a,g   Koenig, Serena P ^f  

^a Centers Institute of Infectious Diseases and Reproductive Health   (Haïti)

^b ANALYSIS GROUP   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e Abt Associates   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; TENOFOVIR;

ADULT; ARTICLE; DISEASE SEVERITY; DRUG COST; FEMALE; HAITI; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

ADULT; AMBULATORY CARE FACILITIES; ANTI-HIV AGENTS; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HAITI; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 84903717101     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000200     Document Type: Article

References (42)

1. Global HIV/AIDS Response: Epidemic Update and Health Sector Progress Towards Universal Access. Geneva, Switzerland: World Health Organization; 2011
2. UNAIDS. UNAIDS World AIDS Day Report, 2012. Geneva, Switzerland: 2012. Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/ epidemiology/2012/gr2012/jc2434-worldaidsday-results-en.pdf. Accessed March 6, 2013
3. El-Sadr WM, Holmes CB, Mugyenyi P, et al. Scale-up of HIV treatment through PEPFAR: a historic public health achievement. J Acquir Immune Defic Syndr. 2012;60(suppl 3):S96-S104
4. Aliyu HB, Chuku NN, Kola-Jebutu A, et al. What is the cost of providing outpatient HIV counseling and testing and antiretroviral therapy services in selected public health facilities in Nigeria? J Acquir Immune Defic Syndr. 2012;61:221-225
5. Beck EJ, Harling G, Gerbase S, et al. The cost of treatment and care for people living with HIV infection: implications of published studies, 1999-2008. Curr Opin HIV AIDS. 2010;5:215-224
6. Bratt JH, Torpey K, Kabaso M, et al. Costs of HIV/AIDS outpatient services delivered through Zambian public health facilities. Trop Med Int Health. 2011;16:110-118
7. Holmes CB, Coggin W, Jamieson D, et al. Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs. JAMA. 2010;304:313-320
8. Holmes CB, Atun R, Avila C, et al. Expanding the generation and use of economic and financial data to improve HIV program planning and efficiency: a global perspective. J Acquir Immune Defic Syndr. 2011;57 (suppl 2):S104-S108
9. Holmes CB, Blandford JM, Sangrujee N, et al. PEPFAR's past and future efforts to cut costs, improve efficiency, and increase the impact of global HIV programs. Health Aff (Millwood). 2012;31:1553-1560
10. Koenig SP, Riviere C, Leger P, et al. The cost of antiretroviral therapy in Haiti. Cost Eff Resour Alloc. 2008;6:3
11. Larson BA, Bii M, Henly-Thomas S, et al. ART treatment costs and retention in care in Kenya: a cohort study in three rural outpatient clinics. J Int AIDS Soc. 2013;16:18026
12. Martinson N, Mohapi L, Bakos D, et al. Costs of providing care for HIVinfected adults in an urban HIV clinic in Soweto, South Africa. J Acquir Immune Defic Syndr. 2009;50:327-330
13. Menzies NA, Berruti AA, Berzon R, et al. The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS. 2011; 25:1753-1760
14. Meyer-Rath G, Miners A, Santos AC, et al. Cost and resource use of patients on antiretroviral therapy in the urban and semiurban public sectors of South Africa. J Acquir Immune Defic Syndr. 2012;61:e25-e32
15. Rosen S, Long L, Sanne I. The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa. Trop Med Int Health. 2008;13:1005-1015
16. Nglazi MD, Lawn SD, Kaplan R, et al. Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa. J Acquir Immune Defic Syndr. 2011;56:e1-e8
17. Medina Lara A, Kigozi J, Amurwon J, et al. Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe. PLoS One. 2012;7:e33672
18. Mugyenyi P, Walker AS, Hakim J, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet. 2010;375:123-131
19. Koenig SP, Schackman BR, Riviere C, et al. Clinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiving antiretroviral therapy in a resource-poor setting. Clin Infect Dis. 2010;51:600-608
20. Hamers RL, Sawyer AW, Tuohy M, et al. Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis. AIDS. 2012;26:1663-1672
21. Long L, Brennan A, Fox MP, et al. Treatment outcomes and costeffectiveness of shifting management of stable ART patients to nurses in South Africa: an observational cohort. PLoS Med. 2011;8:e1001055
22. Brennan A, Long L, Maskew M, et al. Outcomes of stable HIV-positive patients down-referred from doctor-managed ART clinics to nursemanaged primary health clinics for monitoring and treatment. AIDS. 2011;25:2027-2036
23. Sanne I, Orrell C, Fox MP, et al. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet. 2010;376:33-40
24. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2013
25. National Guidelines for the Management of HIV and AIDS. National AIDS Control Programme, Third Edition, Government of Tanzania, 2009
26. Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Recommendations for a Public Health Approahc, 2010 Revision. Geneva, Switzerland: World Health Organization: 2010. Available at: http://whqlibdoc. who.int/publications/2010/9789241599764-eng.pdf. Accessed March 6, 2013
27. Monitoring, Evaluation, and Surveillance Interface. Haiti. Available at: http://www.mesi.ht. Accessed August 28, 2013
28. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programs. 3rd ed. Oxford, United Kingdom: Oxford University Press; 2005
29. World Health Organization Global Price Reporting Mechanism. Available at: http://apps.who.int/hiv/amds/price/hdd/index.aspx. Accessed December 1, 2013
30. International Dispensary Association Foundation. International dispensary association Foundation, 2013 association Foundation. 2009. Available at: http://www.ida.nl/. Accessed April 13, 2013
31. Koenig SP, Bang H, Severe P, et al. Cost-effectiveness of early versus standard antiretroviral therapy in HIV-infected adults in Haiti. PLoS Med. 2011;8:e1001095
32. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363:257-265
33. Crawford KW, Ripin DH, Levin AD, et al. Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement. Lancet Infect Dis. 2012;12:550-560
34. Ford N, Roberts T, Calmy A. Viral load monitoring in resourcelimited settings: a medical and public health priority. AIDS. 2012; 26:1719-1720
35. Keiser O, Chi BH, Gsponer T, et al. Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa. AIDS. 2011;25:1761-1769
36. Riche C, Pape JW, Poitevien, et al. Nurse Practitioner (NP): a new category of specialized personnel to compensate for the shortage of physicians caring for AIDS patients. 2011 Caribbean HIV Conference, November 2011. Nassau, The Bahamas. Available at: https://www.2011caribbeanhivconference.org/abstract/ nurse-practitioner-np-newcategory-specialized-personnel-compensate-shortage- physicians-car. Accessed April 13, 2013
37. Zachariah R, Harries AD, Manzi M, et al. Acceptance of anti-retroviral therapy among patients infected with HIV and tuberculosis in rural Malawi is low and associated with cost of transport. PLoS One. 2006;1:e121
38. Losina E, Toure H, Uhler LM, et al. Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Cote d'Ivoire appraisal. PLoS Med. 2009;6:e1000173
39. Wasti SP, Simkhada P, Randall J, et al. Factors influencing adherence to antiretroviral treatment in Nepal: a mixed-methods study. PLoS One. 2012;7:e35547
40. Bender MA, Kumarasamy N, Mayer KH, et al. Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis. 2010;50:416-425
41. Koenig SP, Rodriguez LA, Bartholomew C, et al. Long-term antiretroviral treatment outcomes in seven countries in the Caribbean. J Acquir Immune Defic Syndr. 2012;59:e60-e71
42. Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med. 2005;353:2325-2334. (Pubitemid 41713744)